4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces its participation in the inaugural Chardan Capital Markets LLC Microbiome Medicines Summit.

Alex Stevenson, 4D’s Chief Scientific Officer, gave a presentation on 4D’s core focus programmes in oncology, gastrointestinal disease, respiratory and CNS disease.

Duncan Peyton, 4D’s Chief Executive Officer, commented: “This is an important year for 4D as we start to see clinical readouts from our lead programmes. Our focus on understanding bacterial function and mechanism to select the most potent single strain Live Biotherapeutics as well as our continued progress to evaluate them in the clinic is reflected in our presentation. 4D’s approach has numerous advantages including accelerated speed into clinical trials and a clear regulatory pathway to market.”

4D has two clinical trials underway in cancer and IBS and expects further trials to commence this year in oncology indications and asthma.

To view the webcast please see: http://wsw.com/webcast/chard3/dddd.l/

For further information please contact:


Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130

Investor Relations ir@4dpharmaplc.com

Zeus Capital Limited - Nomad and Joint Broker

Dab Bate / Jordan Warburton +44 (0) 161 831 1512

Bryan Garnier & Co. Limited - Joint Broker

Dominic Wilson / Phil Walker +44 (0)20 7332 2500

About 4D

Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform that rationally identifies novel bacteria based on a deep understanding of function and mechanism.  All of 4D’s Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.  4D has a phase II study in Irritable Bowel Syndrome and a phase I study in solid tumours open in addition to programmes covering disease areas such as asthma and CNS disease.The Company plans to commence three additional clinical studies in 2019.

For more information, refer to https://www.4dpharmaplc.com/